Who We Are

Our History: Pioneers in the Quest for New Medicines

Soon after the merger of GlaxoSmithKline (GSK) in 2000, we identified that R&D was best done in smaller more productive units and introduced Centres of Excellence for Drug Discovery (CEDDs).

GSK also realized we might not have the monopoly on wisdom when it came to developing new medicines. In order to access the best in the world innovation GSK established a small semi-autonomous scientific investment team of about 20 people in 2005 - the Centre of Excellence for External Drug Discovery, the ceedd. The ceedd considers itself a pioneer in the quest to find new medicines, going to great lengths to actively seek out and collaborate with world-class biotechnology companies.

Bringing More Medicines of Value to Patients

The ceedd was the first team in GSK R&D to be truly externally focused with no internal programs to manage, working across all therapy areas, tasked to form multi-program, risk reward sharing alliances. We thrive on the excitement of discovering innovative scientific platforms and compounds through our collaborations and nurturing them to their full potential to provide the world with differentiated medicines that will deliver significant benefits to patients.